JP2024506347A5 - - Google Patents

Info

Publication number
JP2024506347A5
JP2024506347A5 JP2023548591A JP2023548591A JP2024506347A5 JP 2024506347 A5 JP2024506347 A5 JP 2024506347A5 JP 2023548591 A JP2023548591 A JP 2023548591A JP 2023548591 A JP2023548591 A JP 2023548591A JP 2024506347 A5 JP2024506347 A5 JP 2024506347A5
Authority
JP
Japan
Prior art keywords
patient
pharmaceutical product
product according
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023548591A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506347A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/016254 external-priority patent/WO2022177835A1/en
Publication of JP2024506347A publication Critical patent/JP2024506347A/ja
Publication of JP2024506347A5 publication Critical patent/JP2024506347A5/ja
Pending legal-status Critical Current

Links

JP2023548591A 2021-02-16 2022-02-14 Ｇｄｃ－９５４５およびイパタセルチブを含む併用療法を使用する乳がんの処置 Pending JP2024506347A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163149947P 2021-02-16 2021-02-16
US63/149,947 2021-02-16
PCT/US2022/016254 WO2022177835A1 (en) 2021-02-16 2022-02-14 Treatment of breast cancer using combination therapies comprising gdc-9545 and ipatasertib

Publications (2)

Publication Number Publication Date
JP2024506347A JP2024506347A (ja) 2024-02-13
JP2024506347A5 true JP2024506347A5 (https=) 2025-02-18

Family

ID=80682672

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023548591A Pending JP2024506347A (ja) 2021-02-16 2022-02-14 Ｇｄｃ－９５４５およびイパタセルチブを含む併用療法を使用する乳がんの処置

Country Status (6)

Country Link
US (1) US20230381156A1 (https=)
EP (1) EP4294393A1 (https=)
JP (1) JP2024506347A (https=)
CN (1) CN116847839A (https=)
TW (1) TWI881203B (https=)
WO (1) WO2022177835A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115872996B (zh) * 2023-02-21 2023-05-05 山东绿叶制药有限公司 一种雌激素受体降解剂化合物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109843882A (zh) * 2016-06-16 2019-06-04 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
CR20200621A (es) * 2018-06-21 2021-02-03 Hoffmann La Roche Formas sólidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3 fluoropropil)azetidin-3-il)amino)fenil)-3-(metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol y procesos para preparar compuestos tricíclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos métodos para su uso
JP7571006B2 (ja) 2018-08-17 2024-10-22 ジェネンテック， インコーポレイテッド 乳がんの処置のための診断的および治療的方法
TWI719765B (zh) * 2018-12-19 2021-02-21 美商建南德克公司 使用包含akt抑制劑、紫杉烷及pd-l1抑制劑之組合療法之乳癌治療

Similar Documents

Publication Publication Date Title
JP2022544485A5 (https=)
JP2024015120A5 (https=)
JP2022531898A5 (https=)
JP2018184465A5 (https=)
JP2018035162A5 (https=)
TW202304424A (zh) 包含依維莫司和安森司群的組合
JP2019508476A5 (https=)
EP4322941A1 (en) Combination comprising ribociclib and amcenestrant
JP2024530189A5 (https=)
JP2024533423A5 (https=)
CA3240993A1 (en) Cdk4 inhibitor for the treatment of cancer
JP2023175688A5 (https=)
JP2024102045A5 (https=)
JP2024517085A5 (https=)
JP2024506347A5 (https=)
JP2004525940A (ja) 火照りの処置のためのデュロキセチン
JP2024506385A5 (https=)
JP2022543679A5 (https=)
JP2022177119A5 (https=)
JP2019513706A5 (https=)
JP2011506607A5 (https=)
JP2024539476A5 (https=)
ES2286716T3 (es) Composicion farmaceutica de liberacion controlada y proceso para preparar la misma.
JP2021503448A5 (https=)
AU2017251804A1 (en) Pharmaceutical combinations comprising a PI3K inhibitor for the treatment of cancer